9926: Akeso Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Akeso: 1-Year and 5-Year Forecast Outlook and Rating
Akeso (9926) has an immediate Strong Buy & Keep consensus AI recommendation, based on 11 AI analysts.
The 1-year target is HK$76.3 for , with +34.57% expected return (+34.57% including net dividends) and a STRONG BUY rating.
The 5-year target is HK$115 for , with +102.82% expected return (+102.82% including net dividends) and a STRONG BUY rating.
Latest available market price: HKD 56.7, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 0% (KY). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Akeso Flagship Insight
Domestic Drug Growth Meets the Survival Tollgate for Global Royalties
Akeso's China reimbursement expansion supports recurring oncology growth, while payer price cuts, reinvestment and dilution constrain cash conversion. High consensus centers on domestic scale; overseas valuation remains conditional on prespecified global survival evidence, viable approvals and Akeso's limited contractual royalty share.
How were the Investment Thesis and Forecasts created?
11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Universal Investor (Polymath)
Machiavelli (Insider)
Sherlock Holmes (Whistleblower)
Elon Musk (Visionary)
J.P. Morgan (Titan)
Warren Buffett (Value Purist)
Superintelligence (Anthropologist)
Michael Burry (Vulture)
Ray Dalio (Strategist)
Ran across these frontier AI models
OpenAI GPT-6.1 Sol
Google Gemini 4 Hydrogen
Anthropic Claude Opus 5.5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Akeso: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest HK$10,000 in Akeso at the latest market close (20 Nov 2026): HK$20,282 by Nov 2031.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Benchmark comparison requires matching dated price and currency inputs.
Akeso's investment case is a race between reimbursed Chinese volume and the cost of converting clinical differentiation into cash. Domestic survival evidence and hospital access support recurring growth, but payer concessions and continued research spending limit profit capture. Overseas rights add capital-light optionality, not ownership of Summit's gross sales: Akeso receives contractual royalties and contingent milestones. The starting valuation remains demanding, especially because mixed-currency trailing sales overstate the reported revenue denominator. A disclosed setback in the filed indication strengthens the case for discounting timing rather than assuming immediate global monetization. The strongest counterargument is that frontline global survival success could transform recurring earnings faster than domestic margins suggest.
Key insights
- Partner-funded development protects liquidity but transfers commercial control, making counterparty execution and royalty duration more important than headline global drug-market size.
- Falling selling-cost ratios can coexist with stagnant core losses when reimbursement cuts and weaker treasury income absorb scale benefits; adjusted profitability is insufficient.
- Cash reserves reduce forced-financing risk, not dilution risk; contracted facilities and continued pipeline replacement make growth in earnings per diluted share decisive.
Continue reading Akeso analysis with Base subscription
See Base accessAkeso: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of HKD 56.7, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 0% (KY). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 13 Nov 2026 at HKD 82.3. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD; FX values are exchange rates.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (HKD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (HKD) | Optimistic Advisor Base Case (HKD) | S&P 500 benchmark (USD) | FX (USD/HKD) |
|---|---|---|---|---|---|---|---|---|---|
| HK$69.7 | -15.38% | +22.93% | +22.93% | A setting-specific FDA setback forces investors to push overseas receipts further out, while restrictive financing conditions amplify the valuation reset. Growing Chinese prescriptions cushion the decline, but cannot immediately replace capitalized global royalty expectations. | HK$64.6 | HK$79.1 | $736 | 7.85 | |
| HK$71.0 | +1.95% | +25.22% | +25.22% | Annual results begin rebuilding confidence in Chinese commercial demand, producing a cautious recovery. Continuing factory commitments and research costs limit enthusiasm, while the timing and statistical maturity of global frontline evidence remain unresolved. | HK$60.4 | HK$78.2 | $724 | 7.84 | |
| HK$75.0 | +5.67% | +32.28% | +32.28% | Supportive global frontline updates and expanding Chinese hospital uptake restore some option value. The stronger recovery assumes evidence improves registration visibility, not that progression-free survival automatically establishes overall-survival superiority or guarantees broad Western approval. | HK$65.1 | HK$84.5 | $722 | 7.83 | |
| HK$76.3 | +1.76% | +34.57% | +34.57% | Broader reimbursed indications and domestic launch momentum sustain incremental gains as fixed selling infrastructure supports more prescriptions. Renewal-price negotiations and ongoing clinical spending prevent the market from treating stronger revenue as equivalent growth in distributable earnings. | HK$66.7 | HK$89.6 | $724 | 7.83 | |
| HK$78.2 | +2.40% | +37.92% | +37.92% | Expanding hospital utilization and maturing survival follow-up support further recovery. Reimbursement resets and renewed development budgets remain a meaningful counterweight, especially where optimistic forecasts assume that domestic operating leverage already implies consolidated cash self-sufficiency. | HK$70.6 | HK$94.1 | $735 | 7.82 | |
| HK$82.0 | +4.91% | +44.62% | +44.62% | A clearer overseas registration pathway becomes the principal rerating mechanism, reinforced by improving domestic scale. The scenario rewards reduced timing uncertainty rather than booked royalties, while rival data and cross-border policy risk constrain conviction. | HK$72.8 | HK$101 | $752 | 7.82 | |
| HK$83.8 | +2.18% | +47.80% | +47.80% | Conditional milestone visibility and stronger Chinese product sales improve funding confidence, allowing gains despite competitive readouts and payer pressure. Higher manufacturing utilization matters because existing assets must earn their carrying costs before expansion creates shareholder value. | HK$72.8 | HK$96.8 | $754 | 7.80 | |
| HK$87.6 | +4.49% | +54.50% | +54.50% | Progress toward selective overseas commercialization and broader domestic contribution supports continued appreciation. Cash-generation evidence carries more weight than another pipeline announcement, while commercial launch friction and ongoing research commitments limit the speed of valuation normalization. | HK$77.0 | HK$102 | $780 | 7.80 | |
| HK$91.2 | +4.21% | +60.85% | +60.85% | Improving recurring domestic revenue and conditional Western registration progress reinforce the recovery. Some scenarios begin overseas royalty recognition, while others require longer follow-up; valuation increasingly depends on viable labels and actual adoption rather than headline clinical success. | HK$80.2 | HK$111 | $802 | 7.80 | |
| HK$93.4 | +2.41% | +64.73% | +64.73% | Annual reporting strengthens the domestic cash-conversion case, but payer negotiations and incumbent contracting restrain profit realization. The balance favors measured gains, not an unrestricted rerating, because prescription growth must still absorb research and manufacturing costs. | HK$84.1 | HK$116 | $819 | 7.80 | |
| HK$95.1 | +1.74% | +67.72% | +67.72% | Broader domestic indications and early licensed-market uptake diversify expected cash generation enough to outweigh competitive pressure. The quarter's constructive scenario depends on reduced single-indication concentration, while reimbursement renewals and rival combinations continue limiting terminal market-share assumptions. | HK$81.8 | HK$121 | $821 | 7.79 | |
| HK$98.3 | +3.40% | +73.37% | +73.37% | Recurring earnings and initial overseas receipts gain importance relative to episodic milestones, supporting further valuation repair. Rival launches temper enthusiasm, but improving cash conversion and second-wave clinical progress reduce the financing discount attached to the franchise. | HK$85.7 | HK$117 | $842 | 7.80 | |
| HK$101 | +2.41% | +78.13% | +78.13% | Steadier licensed-market receipts and better Chinese plant utilization support normalized profit expectations. Routine payer resets and stronger competing bispecifics remain material offsets, so the modeled advance reflects operational delivery rather than an assumed permanent scarcity premium. | HK$84.1 | HK$122 | $863 | 7.80 | |
| HK$102 | +1.31% | +79.89% | +79.89% | Improving annual cash generation supports modest appreciation, although new combination-development spending and competitive contracting interrupt margin expansion. The key balance shifts toward reinvestment discipline: growing accounting profits create value only when incremental capital earns acceptable returns. | HK$87.4 | HK$126 | $871 | 7.80 | |
| HK$104 | +2.20% | +83.42% | +83.42% | Broader physician adoption in modeled overseas indications and maturing domestic capacity strengthen recurring earnings visibility. These gains outweigh ongoing reimbursement and competitive pressures, while the scenario does not require a precise interest-rate pivot to sustain support. | HK$90.0 | HK$128 | $874 | 7.80 | |
| HK$107 | +2.56% | +88.71% | +88.71% | Maturing manufacturing investment and expanding royalty contributions improve cash retention, sustaining appreciation despite pricing competition. Pipeline diversification helps preserve growth, but management must demonstrate that new programs complement cash generation rather than restart an equity-funded expansion cycle. | HK$93.6 | HK$126 | $896 | 7.80 | |
| HK$109 | +1.91% | +92.24% | +92.24% | Incremental indication growth and a larger recurring royalty base support modest gains as the business matures. Some scenarios anticipate shareholder distributions, but the central mechanism is stronger cash conversion, not a guaranteed dividend or mechanically accretive repurchase. | HK$92.7 | HK$129 | $912 | 7.81 | |
| HK$110 | +1.32% | +94.00% | +94.00% | Annual earnings demonstrate a more durable commercial base, while normalizing growth limits the multiple investors will pay. Continued cash accumulation supports appreciation, but reinvestment requirements and payer bargaining prevent mature royalties from becoming an unconstrained annuity. | HK$96.4 | HK$132 | $924 | 7.81 | |
| HK$112 | +1.47% | +97.53% | +97.53% | Sustained cash conversion and contained dilution support earnings per share even as legacy oncology growth slows. Next-generation clinical progress offsets some competitive pressure, leaving a modest constructive balance rather than relying on distant patent-cliff fears. | HK$98.3 | HK$133 | $939 | 7.80 | |
| HK$115 | +2.28% | +102.82% | +102.82% | The horizon closes with valuation increasingly anchored to recurring domestic earnings and conditional licensed royalties. Mature-franchise competition and continuing pipeline replacement restrain the multiple, while stronger cash generation supports measured appreciation without assuming global oncology dominance. | HK$101 | HK$135 | $965 | 7.80 |
Show remaining 18 quartersCollapse to first 2 quarters
All 20 quarters are displayed in the table above.
Akeso Stock Analysis & Scenarios Deep Dive
Akeso: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Dated October analyst summaries anticipate a global successor to pembrolizumab, assuming Chinese efficacy translates into Western sales. The predecision share decline nevertheless suggests investors were already less convinced. Reports describe subsequent fear, but not independently verified positioning. Published estimates and traded skepticism therefore conflict; media narratives and options commentary do not establish a precise market-implied approval probability.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The reports establish no compelling directional gap at the supplied anchor, although near-term global cash expectations appear optimistic. The clearest analytical edge is separating recurring Chinese sales from contractual overseas royalties while correcting inconsistent revenue periods and currencies. That makes business growth less synonymous with inexpensive equity. Strong frontline global survival could overturn this caution. Claims of post-rejection undervaluation use a lower entry price and cannot establish cheapness at the anchor.
Repricing Catalyst
What could make the market recognize and close that gap? Prespecified HARMONi-3 survival results, paired with an explicit FDA registration pathway, are the decisive trigger: they replace a clinical story with assessable royalty timing. FY2026 results and 2027 interim sales provide the earlier domestic test. Reports place readouts across 2027–2029, with meaningful disagreement on maturity. Repricing requires consistent regional outcomes and cash conversion; favorable progression-free survival alone may not resolve the filed indication's evidentiary deficit.
Akeso: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Reversal
Most readings indicate fear, erratic volatility and a reversal of regulatory optimism. A smaller group sees stabilization around domestic fundamentals. The decisive timing question is whether commercial cash evidence establishes support before global survival uncertainty produces another valuation reset.
Macro Regime Fit
Does the current market environment support the thesis? The setup is mixed but valuation-adverse. The supplied restrictive-rate backdrop raises the discount on delayed royalties, with Hong Kong financing conditions exposed through the currency peg. Nondiscretionary oncology demand supports prescriptions, but payer budgets constrain prices. Renminbi weakness would dilute translated domestic earnings; eventual dollar royalties offer only a conditional hedge.
Advisor Disagreement
What do our AI Advisors disagree about most? The real economic disagreement is whether global clinical success and moderating spending can overcome reimbursement erosion quickly enough to create substantial per-share cash earnings. The strongest opposing view sees domestic growth financing the transition without immediate Western success. Some disagreement is definitional: inconsistent currencies and half-year periods explain conflicting sales multiples, not different business economics. Supplied partner releases support a regulatory setback, but claims of universal Western exclusion go further. Prespecified, regionally consistent survival evidence and core cash generation after investment would resolve the central dispute.
Thesis Change
What changed in the thesis since the previous forecast? The domestic-growth premise survives, but weaker cash-quality evidence and a disclosed regulatory setback materially reduce confidence in rapid overseas monetization. -- The prior thesis emphasized a self-funding domestic fortress and approaching Western milestones. Current disclosures instead show falling product margins, substantial gross borrowings and equipment commitments, making liquidity resilience different from shareholder insulation. -- The supplied partner update describes a rejection in the filed indication, while currency-consistent revenue checks challenge the repeated sales multiple. Global survival remains the route to royalties, but neither selective approvals nor cash-backed profitability should be treated as assured.
Akeso: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Reimbursement turns access into volume | Regulatory | +40% | +65% | Reimbursed hospital access is the most dependable bridge from clinical efficacy to recurring sales. China's coverage of twelve indications across five self-commercialized drugs supports broader prescribing and new-label uptake. Larger patient volumes should absorb commercial infrastructure over the horizon, although negotiated prices mean revenue will grow more slowly than treatments. |
| Survival evidence defends prescribing relevance | Innovation And Product | +28% | +45% | Established Chinese survival evidence supports physician confidence and the durability of existing indications, independently of Western launch timing. Ivonescimab's comparative results strengthen the domestic franchise and inform additional development. They do not automatically establish global regulatory acceptability; the durable driver is clinical relevance in proven markets, not assured worldwide displacement of incumbents. |
| Scale spreads the fixed bill | Operational Efficiency | +20% | +40% | Falling selling-cost intensity shows that the existing commercial network can support more revenue without proportionate expense. Higher plant utilization offers a second source of cost absorption as domestic volumes expand. Gradual operating leverage is credible, but its conversion into consolidated profit remains contested because payer concessions and continued research consume the savings. |
| Partners fund the overseas option | Capital Allocation | +20% | +30% | Territory licensing shifts much of overseas trial and commercialization spending to Summit while preserving contractual milestones and low-double-digit royalties for Akeso. Strategic backing strengthens the partner's development resources, not Akeso's unrestricted cash. This structure should persist across the horizon, preserving upside while limiting direct spending; it does not guarantee approvals or full product-margin capture. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Survival proof delays royalty cash | Regulatory | -24% | -25% | The filed indication's unmet prespecified survival threshold makes overseas monetization an evidentiary problem, not merely a launch-calendar adjustment. The supplied partner update describes a regulatory setback after the price anchor. Further evidence and review remain necessary, depressing royalty present value, but the evidence does not establish an automatic prohibition across every future indication. |
| Payers buy volume with discounts | Regulatory | -16% | -22% | China's reimbursement expansion exchanges pricing freedom for patient access, leaving durable payer bargaining power over Akeso's largest current revenue stream. Gross-margin erosion shows that more prescriptions need not produce proportional gross profit. Renewals should continue constraining realization, with disagreement centered on whether cost absorption can reliably outrun price concessions. |
| The first-mover clock keeps ticking | Competitive Positioning | -20% | -25% | Well-funded rivals and entrenched checkpoint combinations constrain the scarcity value of ivonescimab even if its clinical profile remains attractive. Longer registration timelines give competitors more time to mature evidence and commercial bundles. Competition should persist throughout the horizon, limiting achievable share, net pricing and the valuation attached to future licensed-market royalties. |
| Reinvestment taxes each shareholder's claim | Capital Allocation | -15% | -15% | Research programs, factory commitments and pipeline replacement require cash before the most valuable potential royalties arrive. A large liquidity buffer limits forced financing but does not remove management's willingness to issue equity. Persistent reinvestment therefore delays distributable cash and can dilute per-share progress, without implying that another raise or financial distress is inevitable. |
Akeso: What Could Break or Accelerate the Thesis
Event Risk Score: High 76/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Global survival fails the tollgate | 35% | -50% | A definitive global frontline efficacy miss or commercially inadequate benefit during 2027–2029 would remove expected royalty value rather than simply delay receipts. Akeso would then rely more heavily on price-constrained Chinese products while continuing to fund research. Existing survival signals keep this a minority scenario; failure need not eliminate every Western indication to cause severe valuation damage. |
| Reimbursement reset breaks the bargain | 30% | -30% | A major reimbursement renewal during 2027–2030 could cut net prices by more than 30% across a material franchise without enough patient growth to compensate. That discrete shock would undermine the domestic self-funding premise, increase plant underutilization and prolong financing needs. It remains a minority outcome because differentiated clinical results and wider access may preserve acceptable product economics. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Global survival unlocks broader registration | 40% | +70% | A prespecified global frontline survival success during 2027–2029, with consistent regional outcomes and an agreed registration route, could convert discounted optionality into broader licensed-market sales. Higher recurring royalties would improve both profit mix and perceived duration. The event remains below half probability because Chinese efficacy and favorable follow-up cannot guarantee statistical replication or commercially broad approvals. |
| Second franchise secures multinational licensing | 30% | +40% | A substantial new licensing agreement for cadonilimab, an ADC or an immunology asset during 2027–2030 could establish a second internationally monetizable franchise. Compelling comparative clinical data and a credible funding counterparty would be the trigger. Upfront cash could reduce financing pressure, but maturity, bargaining terms and cross-border diligence keep the event outside the base case. |
Company Financial AnalysisAkeso: Earnings and Financials Analysis by AI
Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Akeso financials here.
Earnings and financials
Akeso's 2026 interim release reports commercial sales of RMB1.80 billion, up 28.7%, as reimbursement broadens hospital use of its oncology medicines. This is a healthier recurring revenue base than dependence on occasional licensing payments, and lower selling-cost intensity suggests the commercial network is becoming more efficient. However, one reconciliation of the cited HKEX interim accounts attributes much of the narrower net loss to interest and investment income. That tempers claims of a decisive core-profit turnaround. Reported positive interim operating cash flow also differs from free cash flow after investment. The business is progressing, but adjusted profitability is not yet dependable cash available to shareholders.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CNY 3B | CNY -1.1B | CNY -1.8B |
| 2024 | HKD 2.1B | HKD -514.5M | HKD -1.1B |
| 2023 | HKD 4.5B | HKD 2B | CNY 1.6B |
| 2022 | CNY 837.7M | CNY -1.2B | CNY -2B |
| 2021 | CNY 225.6M | CNY -1.1B | CNY -1.7B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | HKD / -- |
| 2024 | 30.6x | TTM | USD-normalized | HKD / -- |
| 2023 | -- | TTM | Unavailable | HKD / -- |
| 2022 | -- | Annual | Loss-making | HKD / CNY |
| 2021 | -- | Annual | Loss-making | HKD / CNY |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Akeso's margin story runs in opposite directions. Supplied FY2025 figures show a 78.7% gross margin, falling to about 74.2% in the first half of 2026 as reimbursement concessions and higher production costs reduce profit per sales yuan. More hospital access is valuable, but the state payer retains bargaining power. Below that line, declining selling-cost intensity shows genuine scale benefits, although consolidated operating earnings remain negative. Reports disagree on how quickly those savings overcome research, depreciation and price cuts; narrower net losses alone do not settle the issue. Eventual overseas royalties could improve profit mix, while one-off milestones should not be mistaken for recurring margin strength.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CNY -918.2M | -30.8% | -36.4% |
| 2024 | HKD -570.4M | -26.9% | -24.2% |
| 2023 | HKD 2B | 45.2% | 44.8% |
| 2022 | CNY -1.3B | -160.0% | -139.5% |
| 2021 | CNY -1.2B | -553.0% | -476.4% |
Balance sheet and leverage
Akeso's 2026 interim disclosures report RMB9.16 billion in cash and short-term financial assets against approximately RMB4.96 billion of bank and other borrowings. The company is liquid, but not debt-free. Gross cash overstates the resources available to absorb setbacks once borrowings, pledged assets and continuing investment commitments are considered. October's equity placement reinforced the cushion, demonstrating access to funding while diluting existing owners. The distinction is between surviving a regulatory delay and protecting each share's eventual earnings. Some reported share purchases involved an employee trust rather than canceled shares, so automatic accretion should not be assumed. Strong liquidity buys management time; it does not eliminate financing or allocation risk.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | CNY 4.6B | CNY 9.2B | CNY 4.3B net cash | CNY -4.6B | 5.14x |
| 2024 | CNY 4B | CNY 7.3B | CNY 2.9B net cash | CNY -3.4B | 5.15x |
| 2023 | CNY 3B | CNY 4.9B | CNY 1.1B net cash | CNY -1.9B | 4.71x |
| 2022 | CNY 1.9B | CNY 2.3B | CNY 213.3M net cash | CNY -412M | 2.25x |
| 2021 | CNY 859.4M | CNY 2.6B | CNY 1.8B net cash | CNY -1.8B | 4.81x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Akeso is still paying to build the business, not merely maintaining established factories. Supplied FY2025 statements imply about RMB712 million of capital expenditure, alongside substantial research spending already charged against profits. Cash therefore leaves through both laboratory expenses and physical investment; combining them would hide their different payback risks. The 2026 Interim Report also records RMB560 million of contracted equipment commitments. That challenges claims that the construction cycle is finished. Better factory utilization could improve cash conversion, but continuing facilities and pipeline commitments extend the wait. Summit funds its own licensed-territory development; that does not erase Akeso's retained manufacturing and research bills.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CNY 712.1M | CNY 1.5B |
| 2024 | HKD 585.8M | HKD 1.2B |
| 2023 | CNY 879.5M | HKD 1.3B |
| 2022 | CNY 775.6M | CNY 1.3B |
| 2021 | CNY 712.1M | CNY 1.1B |
Behind the synthesisAkeso: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.
Company interim disclosures support recurring Chinese prescription growth, while licensing terms establish that overseas value reaches Akeso through royalties and contingent milestones rather than gross partner sales. Financial statements and clinical disclosures support different parts of this mechanism, although repeated press-release coverage is not independent confirmation. The largest weight rewards transparent receipts, consistent periods and explicit contractual economics. Additional weight goes to the reconciliation showing that treasury income helped narrow losses. The strongest bullish counterargument survives: failure in one treated population does not invalidate frontline global potential. However, broad approval, rapid adoption and restrained reinvestment must coincide. The supplied partner update supports a setting-specific setback, not universal Western exclusion. Mixed-currency sales aggregates, automatic repurchase accretion and guaranteed discovery-productivity claims receive little credit. Unresolved survival maturity, reimbursement economics and capital requirements justify retaining all perspectives without allowing repeated assumptions to dominate.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 11 opinions
Consensus weight Allocation: 25.0/100. Weight Allocation Rationale: The highest weight rewards traceable company and SEC receipts, consistent financial periods, explicit royalty assumptions and careful separation of prespecified evidence from favorable follow-up. Distinctive corrections concerning borrowings, commitments and employee-trust purchases survive scrutiny. Terminal earnings and selective approval assumptions remain forecasts, preventing a dominant allocation.
The 1-year target is HK$84.0 for , with +48.18% expected return and a STRONG BUY rating. The 5-year target is HK$122 for , with +115.37% expected return and a STRONG BUY rating.
Consensus weight Allocation: 12.0/100. Weight Allocation Rationale: Linked regulatory updates and the reconciliation of treasury income with narrower losses provide distinctive, decision-relevant evidence. The domestic-sales-versus-overseas-option distinction is especially useful. Weight is restrained by speculative approval probabilities, inconsistent return-hurdle language and claims about strategic funding that the report itself identifies as unverified.
The 1-year target is HK$66.6 for , with +17.55% expected return and a STRONG BUY rating. The 5-year target is HK$109 for , with +92.13% expected return and a STRONG BUY rating.
Consensus weight Allocation: 9.0/100. Weight Allocation Rationale: The report integrates discount-rate sensitivity with the domestic price-volume trade-off and explicitly separates adjusted profitability from cash generation. Its measured recovery is causally plausible. Weight remains limited by repeated mixed-currency aggregates, uncertain assumptions about peak clinical spending and dependence on the same underlying commercial announcements.
The 1-year target is HK$68.0 for , with +19.92% expected return and a STRONG BUY rating. The 5-year target is HK$101 for , with +78.68% expected return and a BUY rating.
Consensus weight Allocation: 8.5/100. Weight Allocation Rationale: The attention to secured borrowings, pledged assets and persistent investment materially improves the liquidity assessment. Its relative weight is moderated by repeated mixed-currency valuation inputs and speculative interpretations of cash compartmentalization, patent outcomes and management motives. The supported balance-sheet cautions remain important despite these limitations.
The 1-year target is HK$80.1 for , with +41.35% expected return and a STRONG BUY rating. The 5-year target is HK$110 for , with +94.65% expected return and a STRONG BUY rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: The domestic volume, reimbursement pressure and dilution mechanisms are economically coherent. However, the valuation repeats a questionable trailing-sales denominator, and insider transactions do not establish advance knowledge of regulatory outcomes. Shared company announcements provide limited independent corroboration, so the useful downside discipline receives a moderate weight.
The 1-year target is HK$68.4 for , with +20.68% expected return and a STRONG BUY rating. The 5-year target is HK$108 for , with +90.85% expected return and a STRONG BUY rating.
Consensus weight Allocation: 8.0/100. Weight Allocation Rationale: The analysis convincingly separates scientific achievement from minority-shareholder cash economics and recognizes recurring reinvestment. However, its valuation retains the disputed trailing-sales figures, while an unchanged diluted share base sits uneasily beside its financing concerns. Extensive sourcing adds context but often traces back to shared corporate announcements.
The 1-year target is HK$77.3 for , with +36.39% expected return and a STRONG BUY rating. The 5-year target is HK$114 for , with +100.26% expected return and a STRONG BUY rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: The strongest contribution is distinguishing frontline clinical potential from the rejected post-treatment indication. That distinction survives scrutiny and preserves meaningful upside. However, rapid registration, broad adoption and unusually large earnings effects require several favorable outcomes, while repeated announcements and inconsistent revenue units weaken the numerical foundation.
The 1-year target is HK$89.7 for , with +58.19% expected return and a STRONG BUY rating. The 5-year target is HK$135 for , with +137.43% expected return and a STRONG BUY rating.
Consensus weight Allocation: 6.5/100. Weight Allocation Rationale: Recurring Chinese demand and the distinction between a narrow regulatory setback and platform-wide failure are valuable. Nevertheless, repeated sales aggregates, unproven discovery-productivity benefits and confident cash-conversion claims weaken the path. The sourcing largely recycles common announcements rather than independently establishing the more ambitious operational conclusions.
The 1-year target is HK$69.7 for , with +23.00% expected return and a STRONG BUY rating. The 5-year target is HK$112 for , with +98.20% expected return and a STRONG BUY rating.
Consensus weight Allocation: 6.0/100. Weight Allocation Rationale: The analysis correctly connects reimbursement access, partner-funded trials and cross-border exposure. Its relative weight is reduced because monopoly language, legislative certainty and inferred management motives exceed the supplied evidence. Much of the sourcing overlaps other reports, while geopolitical scenarios lack sufficiently specific support for their asserted implementation.
The 1-year target is HK$72.2 for , with +27.27% expected return and a STRONG BUY rating. The 5-year target is HK$105 for , with +85.62% expected return and a STRONG BUY rating.
Consensus weight Allocation: 5.5/100. Weight Allocation Rationale: The report identifies genuine commercial scale benefits and the partner's role in financing overseas development. Its lower weight reflects unsupported productivity premiums, overstatement of regulatory generalizations and aggressive assumptions about capital payback. Clinical differentiation is retained, but engineering narratives do not independently validate shareholder economics.
The 1-year target is HK$70.6 for , with +24.50% expected return and a STRONG BUY rating. The 5-year target is HK$106 for , with +86.71% expected return and a STRONG BUY rating.
Consensus weight Allocation: 4.5/100. Weight Allocation Rationale: The focus on distributable cash and per-share value is sound, and the gradual commercialization mechanism remains useful. The lowest weight reflects absent linked receipts, overstated pricing power and repurchase assumptions challenged by employee-trust disclosures. Limited source independence and insufficient treatment of ongoing commitments weaken the claimed capital discipline.
The 1-year target is HK$82.9 for , with +46.28% expected return and a STRONG BUY rating. The 5-year target is HK$107 for , with +88.16% expected return and a STRONG BUY rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Akeso forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (91 recorded). The first 15 are shown below; expand to read the rest.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- clinicaltrials.gov clinicaltrials.gov
- sec.gov sec.gov
- https://www.sec.gov/Archives/edgar/data/1599298/000159929826000006/a2026_prx0129xfdablaacce.htm?utm_source=openai sec.gov
- https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/a2026_prx0913xharmoni-2o.htm?utm_source=openai sec.gov
- https://www.sec.gov/Archives/edgar/data/1599298/000159929826000081/a2026_prx0915xharmoniltf.htm?utm_source=openai sec.gov
- smmt-20260930 sec.gov
- prnewswire.com prnewswire.com
- fiercepharma.com fiercepharma.com
- smmttx.com smmttx.com
- biospace.com biospace.com
- allsci.com allsci.com
- biggo.com biggo.com
- hkexnews.hk hkexnews.hk
- 36kr.com 36kr.com
- firstwordpharma.com firstwordpharma.com
Show 25 more sources
- pharmaphorum.com pharmaphorum.com
- visionlifesciences.com visionlifesciences.com
- futunn.com futunn.com
- investing.com investing.com
- perplexity.ai perplexity.ai
- quartr.com quartr.com
- cmbi.info cmbi.info
- cooley.com cooley.com
- endpoints.news endpoints.news
- longbridge.com longbridge.com
- yicaiglobal.com yicaiglobal.com
- biopharmaapac.com biopharmaapac.com
- chinapharmadesk.com chinapharmadesk.com
- pienomial.com pienomial.com
- publicnow.com publicnow.com
- stockanalysis.com stockanalysis.com
- tradingview.com tradingview.com
- vcbeathealth.com vcbeathealth.com
- biopharminternational.com biopharminternational.com
- etnet.com.hk etnet.com.hk
- fiercebiotech.com fiercebiotech.com
- insights.bio insights.bio
- kolpulse.com kolpulse.com
- moomoo.com moomoo.com
- patsnap.com patsnap.com
51 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through November 14
Download Archived SnapshotCoverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14
January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.
Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 96K bytes
- Words
- 14.2K words
- Characters
- 96K characters
- Est. tokens (characters ÷ 4)
- 24K tokens
Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| US tariff reset, trade truce and incoming divided government | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2018-12-31–2025-12-31, 8 periods; Quarterly fiscal periods: 2023-12-31–2026-06-30, 6 periods.
Currencies cited: CNY, HKD, USD (quote HKD; primary reporting CNY; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Akeso: forecast questions
What is Akeso (9926)'s 1-year price forecast?
Akeso's 1-year target is HK$76.3 for Nov 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +34.57%, or +34.57% modeled return including net dividends. Latest available market price: HKD 56.7, as of 20 Nov 2026. The target date is fixed at publication.
What is Akeso (9926)'s 5-year price forecast?
Akeso's 5-year target is HK$115 for Nov 2031. The current AI rating is STRONG BUY. The expected return from the recorded close is +102.82%, or +102.82% modeled return including net dividends. Latest available market price: HKD 56.7, as of 20 Nov 2026. The target date is fixed at publication.
How can I compare the AI opinions and audit past Akeso forecasts?
11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.
How does an AI-generated forecast for Akeso differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Akeso is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.








